{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-079487","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.905601+00:00","generated_at":"2026-06-21T05:33:23.191684+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InMed appoints interim CFO and replaces auditor KPMG with Marcum","bullets":["Jonathan Tegge appointed Interim CFO via Brio; monthly fee $9,750. Effective Dec 12, 2022.","KPMG resigned as auditor (Dec 8, 2022); InMed engaged Marcum LLP as replacement, subject to acceptance.","Annual Meeting Dec 15, 2022; management to recommend Marcum appointment using discretionary proxy.","Options granted: 1,400 fully vested shares to Brio; 1,400 shares vesting monthly over 12 months to Tegge."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-079487","json":"https://secwatch.observer/filing/0001213900-22-079487.json","markdown":"https://secwatch.observer/filing/0001213900-22-079487.md","text":"https://secwatch.observer/filing/0001213900-22-079487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022079487/0001213900-22-079487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022079487/ea170120-8k_inmedpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:33:23.191684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d35b867f77","claim":"Jonathan Tegge was appointed as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"As described above, the Company appointed Mr. Tegge as Interim Chief Financial Officer of the Company effective December 12, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022079487/0001213900-22-079487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}